Future Fields
Future Fields is revolutionising the biomanufacturing process by utilising nature's systems, specifically with fruit flies, in combination with advanced genetic engineering techniques. Unlike conventional methods that rely on resource-intensive systems such as E. Coli and CHO, Future Fields has harnessed the potential of the fruit fly through innovative fly farming techniques. This novel approach, referred to as the EntoEngine ™ marks a pioneering achievement in the field.
View all Future Fields Products
Future Fields is revolutionising the biomanufacturing process by utilising fruit flies in combination with advanced genetic engineering techniques. Unlike conventional methods that rely on resource-intensive systems such as E. Coli and CHO, Future Fields has harnessed the potential of the fruit fly through innovative fly farming techniques referred to as the EntoEngine™ technology that uses engineered fruit flies to produce high‐quality, recombinant proteins. This marks as a unique and pioneering achievement in the field of recombinant protein development.
Future Fields Recombinant Protein Engineering Platform and Custom Services
Their accomplishments began with the development of Human and Bovine FGF2 but has now taken a leap towards including custom recombinant protein services that is designed to address the challenges of producing difficult‐to‐express proteins while offering a flexible, scalable, and cost‐effective solution for research, pre‐clinical, and industrial applications across various market verticals.
The hard work and revolutionary platform Future Fields offer have been acknowledged by Forbes, in which they detail the difficulties of more traditional methods of synthesising recombinant proteins and explain how many issues in this process, such as scaling and costs, is largely resolved with Future Fields ground-breaking progress. For the full Forbes article, please visit this page.
Addressing the pressing concern of sustainability, the company has also embraced a pivotal role in "1% for the Planet" a renowned philanthropic organisation. Furthermore, they have spearheaded assessments within their field, setting an industry precedent by being the first in the growth factors industry with their "ACT" initiative. See below for more details on their sustainable values.
The Ento-Engine Platform - Future Fields Custom Protein Manufacturing Services which sets them apart from other Protein development services, by addressing key challenges the Protein expression landscape faces that the EntoEngine™ platform can help solve for future protein developments. They are explained below.
● Difficult-to-Express Proteins (DTEPs) that are otherwise challenging in traditional systems
The EntoEngine™ allows for unique expression environments across 200+ cell types. The extensive library of available and custom drivers allows for targeted expression approaches that are not available in alternative expression systems. For example, the EntoEngine™ can make use of unique extracellular environments where host chaperones or ideal cell type(s) are plentiful. Click here for a deep dive on the EntoEngine™ system’s genetic advantages.
● Host-Cell Toxicity offers greater challenges for protein yield and viable expression strains
The EntoEngine’s approach to inducible expression exploits gentle thermal stress, effectively turning on expression when it is needed. This can be coupled to specific tissue targeting, or ubiquitous expression, permitting production of proteins that are historically sensitive, misfolding prone, or toxic when overexpressed. Using a thermal induction method allows for affordable expression control, in contrast to traditional chemical induction methods. Click here for an article comparing the EntoEngine™ with six other conventional expression systems.
● Scalability remains a challenge in difficult to express proteins as low to no yields causes manufacturing constraints
The EntoEngine™ is a modular system that does not have the scaling constraints or process fragility of bioreactors. This unique upstream allows for modular, redundant, and predictable scaling, circumventing many challenges experienced by alternative approaches. The system can be used for both process development and follow-on production at commercial scales.
● Cost-Efficiency is a key priority in protein development where time, scale-up and batch loss become important factors to consider in manufacturing process
As many variables must be optimised at each jump in scale, including complex media formulations the EntoEngine’s unique insect upstream uses a simple input stream built on a stable supply chain. The result is the same strain that was used for product development is used throughout the entire process, with no per-protein optimisation needed for media development. Fly strains are managed at lower temperatures than bioreactor media, saving energy and water costs compared to conventional methods. This new paradigm allows Future Fields to share these cost savings with customers, opening accessibility in protein biomanufacturing.
Therefore, all available products from Future Fields demonstrate high levels of performance and consistency with a broad range of benefits including a 95% purity level that showcases consistent cell proliferation from batch to batch and exhibits a wide safety margin and larger scalability of proteins with high performance without breaking the budget.
Featured Products
Produced within Future Fields' eco-friendly, bioreactor-free certified laboratory, these growth factor present an opportunity for researchers to access a sustainable, cost-effective, and exceptionally capable solution. For further information on Future Fields products, please visit their performance report here.
